======= TBX21 =======
== Gene Information ==
* **Official Symbol**: TBX21
* **Official Name**: T-box transcription factor 21
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=30009|30009]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9UL17|Q9UL17]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=TBX21&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TBX21|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/604895|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene is a member of a phylogenetically conserved family of genes that share a common DNA-binding domain, the T-box. T-box genes encode transcription factors involved in the regulation of developmental processes. This gene is the human ortholog of mouse Tbx21/Tbet gene. Studies in mouse show that Tbx21 protein is a Th1 cell-specific transcription factor that controls the expression of the hallmark Th1 cytokine, interferon-gamma (IFNG). Expression of the human ortholog also correlates with IFNG expression in Th1 and natural killer cells, suggesting a role for this gene in initiating Th1 lineage development from naive Th precursor cells. [provided by RefSeq, Jul 2008].
* **UniProt Summary**: Lineage-defining transcription factor which initiates Th1 lineage development from naive Th precursor cells both by activating Th1 genetic programs and by repressing the opposing Th2 and Th17 genetic programs (PubMed:10761931). Activates transcription of a set of genes important for Th1 cell function, including those encoding IFN-gamma and the chemokine receptor CXCR3. Activates IFNG and CXCR3 genes in part by recruiting chromatin remodeling complexes including KDM6B, a SMARCA4- containing SWI/SNF-complex, and an H3K4me2-methyltransferase complex to their promoters and all of these complexes serve to establish a more permissive chromatin state conducive with transcriptional activation (By similarity). Can activate Th1 genes also via recruitment of Mediator complex and P-TEFb (composed of CDK9 and CCNT1/cyclin-T1) in the form of the super elongation complex (SEC) to super-enhancers and associated genes in activated Th1 cells (PubMed:27292648). Inhibits the Th17 cell lineage commitment by blocking RUNX1-mediated transactivation of Th17 cell-specific transcriptinal regulator RORC. Inhibits the Th2 cell lineage commitment by suppressing the production of Th2 cytokines, such as IL-4, IL-5, and IL- 13, via repression of transcriptional regulators GATA3 and NFATC2. Protects Th1 cells from amplifying aberrant type-I IFN response in an IFN-gamma abundant microenvironment by acting as a repressor of type-I IFN transcription factors and type-I IFN-stimulated genes. Acts as a regulator of antiviral B-cell responses; controls chronic viral infection by promoting the antiviral antibody IgG2a isotype switching and via regulation of a broad antiviral gene expression program (By similarity). {ECO:0000250|UniProtKB:Q9JKD8, ECO:0000269|PubMed:10761931, ECO:0000269|PubMed:27292648}.
|T-box|
|negative regulation of T-helper 17 cell lineage commitment|
|negative regulation of T-helper 2 cell cytokine production|
|regulation of T-helper 17 cell lineage commitment|
|negative regulation of T cell cytokine production|
|negative regulation of T-helper 17 cell differentiation|
|negative regulation of T-helper 17 type immune response|
|positive regulation of isotype switching to IgG isotypes|
|regulation of T-helper 2 cell cytokine production|
|regulation of isotype switching to IgG isotypes|
|negative regulation of type 2 immune response|
|negative regulation of cell fate commitment|
|negative regulation of T-helper cell differentiation|
|regulation of T-helper 17 cell differentiation|
|negative regulation of T cell mediated immunity|
|regulation of T-helper 17 type immune response|
|negative regulation of CD4-positive, alpha-beta T cell differentiation|
|negative regulation of interleukin-2 production|
|negative regulation of alpha-beta T cell differentiation|
|positive regulation of isotype switching|
|negative regulation of cytokine production involved in immune response|
|regulation of cell fate commitment|
|negative regulation of CD4-positive, alpha-beta T cell activation|
|regulation of type 2 immune response|
|regulation of T cell cytokine production|
|regulation of isotype switching|
|regulation of T-helper cell differentiation|
|negative regulation of production of molecular mediator of immune response|
|positive regulation of immunoglobulin mediated immune response|
|positive regulation of B cell mediated immunity|
|negative regulation of lymphocyte mediated immunity|
|negative regulation of alpha-beta T cell activation|
|positive regulation of DNA recombination|
|negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|positive regulation of immunoglobulin production|
|negative regulation of T cell differentiation|
|negative regulation of adaptive immune response|
|regulation of CD4-positive, alpha-beta T cell differentiation|
|negative regulation of leukocyte mediated immunity|
|regulation of B cell mediated immunity|
|regulation of immunoglobulin mediated immune response|
|negative regulation of lymphocyte differentiation|
|RNA polymerase II activating transcription factor binding|
|regulation of interleukin-2 production|
|regulation of CD4-positive, alpha-beta T cell activation|
|regulation of alpha-beta T cell differentiation|
|regulation of immunoglobulin production|
|lymphocyte migration|
|regulation of T cell mediated immunity|
|regulation of cytokine production involved in immune response|
|cell fate specification|
|regulation of alpha-beta T cell activation|
|positive regulation of production of molecular mediator of immune response|
|positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|negative regulation of leukocyte differentiation|
|regulation of DNA recombination|
|positive regulation of adaptive immune response|
|positive regulation of lymphocyte mediated immunity|
|negative regulation of T cell activation|
|negative regulation of immune effector process|
|negative regulation of leukocyte cell-cell adhesion|
|positive regulation of leukocyte mediated immunity|
|T cell differentiation|
|negative regulation of hemopoiesis|
|regulation of T cell differentiation|
|regulation of production of molecular mediator of immune response|
|regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|negative regulation of lymphocyte activation|
|negative regulation of immune response|
|regulation of lymphocyte mediated immunity|
|regulation of adaptive immune response|
|positive regulation of B cell activation|
|regulation of lymphocyte differentiation|
|negative regulation of cell-cell adhesion|
|negative regulation of leukocyte activation|
|positive regulation of DNA metabolic process|
|negative regulation of cell activation|
|regulation of leukocyte mediated immunity|
|regulation of B cell activation|
|transcription regulatory region DNA binding|
|positive regulation of immune effector process|
|T cell activation|
|lymphocyte differentiation|
|DNA-binding transcription repressor activity, RNA polymerase II-specific|
|cell fate commitment|
|regulation of leukocyte differentiation|
|negative regulation of cell adhesion|
|negative regulation of cytokine production|
|response to virus|
|regulation of leukocyte cell-cell adhesion|
|RNA polymerase II regulatory region sequence-specific DNA binding|
|regulation of T cell activation|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|leukocyte differentiation|
|proteasomal protein catabolic process|
|regulation of DNA metabolic process|
|positive regulation of lymphocyte activation|
|neuronal cell body|
|leukocyte migration|
|lymphocyte activation|
|regulation of cell-cell adhesion|
|positive regulation of leukocyte activation|
|positive regulation of cell activation|
|sequence-specific DNA binding|
|negative regulation of immune system process|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|regulation of hemopoiesis|
|regulation of immune effector process|
|regulation of lymphocyte activation|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|hemopoiesis|
|proteolysis involved in cellular protein catabolic process|
|regulation of leukocyte activation|
|hematopoietic or lymphoid organ development|
|cellular protein catabolic process|
|regulation of cell activation|
|immune system development|
|DNA-binding transcription factor activity|
|regulation of cell adhesion|
|protein catabolic process|
|regulation of cytokine production|
|negative regulation of cell differentiation|
|negative regulation of transcription by RNA polymerase II|
|positive regulation of immune response|
|cellular macromolecule catabolic process|
|leukocyte activation|
|negative regulation of developmental process|
|cell migration|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|cell activation|
|localization of cell|
|cell motility|
|positive regulation of immune system process|
|regulation of immune response|
|negative regulation of transcription, DNA-templated|
|negative regulation of multicellular organismal process|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|proteolysis|
|response to other organism|
|response to external biotic stimulus|
|locomotion|
|response to biotic stimulus|
|negative regulation of RNA metabolic process|
|positive regulation of developmental process|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|movement of cell or subcellular component|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|negative regulation of response to stimulus|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|regulation of immune system process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|positive regulation of multicellular organismal process|
|organic substance catabolic process|
|cellular catabolic process|
|regulation of cell differentiation|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp288|HMS-I2 10μM R06 exp288]]|-2.29|
|[[:results:exp462|Cadmium 60μM R08 exp462]]|-2.19|
|[[:results:exp534|Trientine 500μM R08 exp534]]|-1.8|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 15282
* **Expression level (log2 read counts)**: -6.02
{{:chemogenomics:nalm6 dist.png?nolink |}}